Citations

Clear

75 citation(s) found for "Lee, Hong".

Erratum to: Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus Diffuse Frontal Atrophy
Lee, Jin San , Jang, Young Kyoung, Kim, Hee Jin, Seo, Sang Won , Kim, Yeo Jin , Park, Kyung-Won, Yoon, Soo Jin , Kim, Seung Hyun , Park, Key‐Chung , Na, Duk L. , Jung, Na‐Yeon , Kim, Hee Jin, Lee, Juyoun , Lee, Jae‐Hong , Kim, Byeong Chae , Park, Kyung-Won, Yoon, Soo Jin , Kim, SangYun , Kim, Eun‐Joo , Knopman, David S.

Mayo Clinic

Journal of Clinical Neurology | October 22, 2017 | Volume: 13 | Issue: 4 | Pages: 447

10.3988/jcn.2017.13.4.447 | PMID 29057638 Get It

Abstract LB-274: Whole-exome sequencing reveals tyrosine kinase-resistant mutations in pretreatment EGFR-mutant lung adenocarcinomas
Gao, Xuyuan , Xu, Hang , Chan, Oscar SH, Xu, Feng , Wang, Junwen , Tin, Vicky Pc, Xiao, Zhijie , Wang, Siqi , Wong, Maria Pik , Wang, Junwen , Ho, Jcm , Lee, Victor , Yam, Judy Wai Ping

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: LB-274-LB-274

10.1158/1538-7445.am2017-lb-274 Get It

Abstract Lung cancer is the most lethal malignancy around the world. In Hong Kong, chronic tobacco use is prevalent in male but <20% of female patients smoke. Epidermal growth factor receptor (EGFR) mutations affect 30% and 67% of male and female lung adenocarcinomas, respectively. Treatment responses to tyrosine kinase inhibitors (TKI) are not uniform and all patients eventually develop drug resistance. Mutation screening of immediate pre-treatment tumors is the most ideal for assessing drug targets but in practice, excision specimens of primary or metastatic sites are more efficient in terms of tumor quantity, timeliness and patient acceptance. However, information on the applicability of this approach and correlation with the clinical outcome is limited. For this purpose, we compared the whole exome mutation profiles of 39 excised EGFR mutant cancers treated with first line TKI with the clinical response type, including 15 stage I/II and 24 stage III/IV tumors. They included 16 non-responders (NR) defined clinically as those with stable or progressive disease, and 23 responders (R) defined by partial or complete tumor shrinkage. Considering only the non-synonymous SNV and INDEL mutations of coding regions of known actionable targets and genes listed in both the CGC and COSMIC cancer databases, the tumors harbored 54 mutated genes including 26 recurrently mutated and 28 genes involving only 1 tumor. Excluding EGFR, TP53 was the most commonly mutated gene occurring in 25/39 (64.1%) cases. Most known resistant genes involved in the EGFR and bypass signaling network showed mutations only in the NR group including recurrent mutations of PTEN (3/16), PIK3CA (2/16) and NF1 (2/16), and single case mutations of AKT1, ALK, RAF1 and KDR. Two EGFR network candidates showed mutations in both the NR and R groups, including HGF (2/16 NR, 1/23 R) and ROS1 (1 case in either group). Four post-treatment (post-TKI) tumors of acquired resistance were also analyzed, all of which showed EGFR T790M while no pre-treatment NR or R tumor harbored this mutation. Notably, mutations in the β-catenin pathway were prominent in the NR and post-TKI tumors, including APC (2/16 NR), CTNNB1 (1/16 NR, 1/4 post-TKI) and c-MYC (1/16 NR, 1/4 post-TKI) while they were not detected in the R tumors. Also, nonsense mutations of ARID1A was observed in 2/16 NR but none of the R tumors. In summary, our findings revealed candidate TKI resistant mutations involving the EGFR and bypass signaling networks in pre-treatment excision specimens particularly in non-responding patients. The EGFR T790M was not detectable in pre-treatment samples but was prevalent in post-TKI treated cancers. While this study is limited by its small cohort size, the findings indicate deep sequencing analysis of pre-treatment excision specimens of EGFR-mutant lung adenocarcinomas is warranted for detection of resistant mutations and predicting treatment response. Note: This abstract was not presented at the meeting. Citation Format: Xu-yuan Gao, Hang Xu, James CM Ho, Oscar SH Chan, Feng Xu, Junwen Wang, Victor HF Lee, Vicky PC Tin, Zhijie Xiao, Siqi Wang, Judy WP Yam, Maria P. Wong. Whole-exome sequencing reveals tyrosine kinase-resistant mutations in pretreatment EGFR-mutant lung adenocarcinomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-274. doi:10.1158/1538-7445.AM2017-LB-274
Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus Diffuse Frontal Atrophy
Lee, Jin San , Jang, Young Kyoung, Kim, Hee Jin, Seo, Sang Won , Lee, Juyoun , Kim, Yeo Jin , Park, Kyung-Won, Yoon, Soo Jin , Kim, Seung Hyun , Park, Key‐Chung , Knopman, David S. , Na, Duk L. , Jung, Na‐Yeon , Kim, Hee Jin, Lee, Jae‐Hong , Kim, Byeong Chae , Yoon, Soo Jin , Kim, SangYun , Kim, Eun‐Joo , Knopman, David S.

Mayo Clinic

Journal of Clinical Neurology | July 26, 2017 | Volume: 13 | Issue: 3 | Pages: 234

10.3988/jcn.2017.13.3.234 | PMID 28748674 Get It

Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Landen, Jaren W., Cohen, Sharon , Billing, Clare B., Cronenberger, Carol, Styren, Scot, Burstein, Aaron H. , Sattler, Catherine, Kantarci, Kejal , Schwartz, Pamela F., Duggan, William, Zhao, Qinying, Sprenger, Ken, Bednar, Martin M., Binneman, Brendon, Lee, Jae‐Hong , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 11, 2017 | Volume: 3 | Issue: 3 | Pages: 339-347

10.1016/j.trci.2017.04.003 | PMID 29067341 Get It

Abstract Introduction Multiple intravenous doses of ponezumab, an anti‐amyloid antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's disease (AD). Methods In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed for 6 months thereafter. Results Ponezumab was generally safe and well tolerated. Most common adverse events were fall (16.7% ponezumab, 21.4% placebo), headache (13.8%, 21.4%), and cerebral microhemorrhage (13.8%, 19.6%). Plasma ponezumab increased dose‐dependently with limited accumulation. Cerebrospinal fluid penetration was low. Plasma Aβ 1–x and Aβ 1–40 showed robust increases, but cerebrospinal fluid biomarkers showed no dose response. Ponezumab had no effects on cognitive/functional outcomes or brain volume. Conclusions Multiple‐dose ponezumab was generally safe, but not efficacious, in mild‐to‐moderate AD.
The diagnostic criteria of pityriasis rosea and Gianotti-Crosti syndrome – a protocol to establish diagnostic criteria of skin diseases
Chuh, Antonio , Zawar, Vijay , Sciallis, GF, Lee, A, Sciallis, GF

Mayo Clinic

Journal of the Royal College of Physicians of Edinburgh | April 24, 2017 | Volume: 45 | Issue: 3 | Pages: 218-225

10.4997/jrcpe.2015.310 | PMID 26517103 Get It

We established and validated diagnostic criteria for pityriasis rosea and Gianotti-Crosti syndrome. In this paper, we compare and contrast both diagnostic criteria to formulate a protocol in establishing diagnostic criteria for other dermatological diseases. The diagnostic criteria are similar in employing clear dividing lines and conjunctions (‘and/or') to assure high reliability. Both sets of criteria should be applicable for all ethnic groups. Spontaneous remission is not included, so diagnosis is not delayed while waiting for disease remission. Laboratory investigations are not enlisted, so that the criteria can be used in medical care systems in different parts of the world. The diagnostic criteria are different in that pathognomonic clinical manifestations exist for pityriasis rosea, such as the herald patch and the orientation of lesions along the lines of skin cleavages. These features, however, score low for sensitivity. These specific manifestations are not seen in Gianotti-Crosti syndrome. Such differences led to different categorisation of clinical features. Atypical variants are more common for pityriasis rosea. The diagnostic criteria for pityriasis rosea therefore do not include a list of differential diagnoses, while diagnostic criteria for Gianotti-Crosti syndrome do. Using this comparison, we constructed a protocol to establish diagnostic criteria for other skin diseases. We advocate the need to justify the establishment of diagnostic criteria, that multiple diagnostic criteria for the same disease should be avoided, that diagnostic criteria should be compatible with the disease classification if applicable, and that the scope should be well-delineated with regard to clinical variants. We outline the need for validation studies to assess the criteria-related validity, test-retest intra-clinician reliability, and inter-clinician reliability. We emphasise that the establishment of diagnostic criteria should not be a generic process. We also highlight limitations of diagnostic criteria, and emphasise that no diagnostic criteria can replace the bedside experience of clinicians.
Survey of Current Practices from the International Stereotactic Body Radiotherapy Consortium (Isbrtc) for Head and Neck Cancers
Karam, Irene , Yao, Min , Heron, Dwight E. , Poon, Ian , Koyfman, Shlomo A. , Yom, Sue S. , Siddiqui, Farzan , Lartigau, Éric, Cengiz, Mustafa , Yamazaki, Hideya , Hara, Wendy, Phan, Jack , Vargo, John A. , Lee, Victor , Foote, Robert L. , Harter, K. William, Lee, Nancy Y. , Sahgal, Arjun , Lo, Simon S. , Yom, Sue S , Phan, Jack

Mayo Clinic

Future Oncology | November 15, 2016 | Volume: 13 | Issue: 7 | Pages: 603-613

10.2217/fon-2016-0403 | PMID 27842456 Get It

P4‐219: The Diffuse, Not Focal, Frontal Atrophy Subtype Shows Worse Prognosis in Frontotemporal Dementia
Lee, Jin San , Jung, Na Yeon, Jang, Young Kyoung, Kim, Yeo Jin , Kim, Hee Jin , Seo, Sang Won , Park, Kyung-Won, Yoon, Soo Jin , Park, Key‐Chung , Na, Duk L. , Jung, Na‐Yeon , Kim, Eun Joo , Lee, Juyoun , Lee, Jae‐Hong , Kim, Byeong Chae , Park, Kyung-Won, Yoon, Soo Jin , Kim, SangYun , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_23 | Pages: No page available

10.1016/j.jalz.2016.06.2311 Get It

Abstract 1003: Targeting liver-tumor initiating cells via hampering the lipogenesis pathways through stearoyl - CoA desaturase
Fai, Kin, Lo, Jessica, Copland, John A. , Lau, Eunice Yuen-Ting , Ng, Irene Oi‐Lin , Lee, Terence K.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 1003-1003

10.1158/1538-7445.am2016-1003 Get It

Abstract Hepatocellular carcinoma is one of the most lethal cancers in the world. Most of the patients are diagnosed at advanced stage, and they receive sorafenib as their treatment modality. However, sorafenib can only extend patients’ survival to a median of 3-4 months. Hence, there is an urgent need to identify a new therapeutic target for treatment of this disease. Increasing evidence showed that tumor-initiating cells (T-ICs) are intrinsically resistant to conventional treatments. Identification of the signalling pathways that maintain the functions of T-ICs provides potential targets for treatment of HCC. For this purpose, we cultured serial passages of hepatospheres combined with chemotherapeutic regimens as a strategy to enrich liver T-IC population. Using cDNA microarray, we found upregulation of several key enzymes in lipogenesis in enriched T-IC population, among which Stearoyl CoA desaturase-1 (SCD1), the enzyme involved in the conversion of saturated into monounsaturated fatty acids, was the most significant. In HCC clinical samples, 62% (36/58) was found to be overexpressed (> 2-fold) when compared with non-tumor counterparts and patients with SCD1 overexpression had shorter disease free survival. Using overexpression and knockdown approaches, SCD1 was found to regulate the traits of T-ICs, including tumorigenicity, self-renewal, drug resistance and expression of liver T-IC markers. SCD1 was found critical in survival of T-ICs, as enriched T-IC population are more sensitive to the inhibition of SCD1 compared to adherent lineages. Interestingly, SCD1 was found to be upregulated in sorafenib-resistant HCC cells. Pharmacological inhibition of SCD1 by A939572 not only suppressed self-renewal ability but also consistently enhanced the sensitivity towards sorafenib. Using a patient-derived xenograft model, we found that a new inhibitor against SCD1 demonstrated significant growth suppressive effect. By comparing the genetic profiles between SCD1 knockdown cells and control cells by RNA sequencing analysis, we found that upregulation of ER stress signature genes may be the potential downstream targets of SCD1 to maintain the properties of T-ICs. In conclusion, we demonstrated the crucial role of SCD1 in maintenance of liver T-ICs, and targeting SCD1 in combination with sorafenib might be a novel therapeutic regimen against HCC. Citation Format: Kin Fai Ma, Jessica Lo, Eunice Yuen-Ting Lau, John A. Copland, Irene Oi-Lin Ng, Terence Kin-Wah Lee. Targeting liver-tumor initiating cells via hampering the lipogenesis pathways through stearoyl - CoA desaturase. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1003.
Is Gianotti–Crosti Syndrome Associated with Atopy? A Case–Control Study and a Postulation on the Intrinsic Host Factors in Gianotti–Crosti Syndrome
Chuh, Antonio , Zawar, Vijay , Sciallis, Gabriel F., Sciallis, Gabriel, Lee, Albert

Mayo Clinic

Pediatric Dermatology | June 25, 2016 | Volume: 33 | Issue: 5 | Pages: 488-492

10.1111/pde.12886 | PMID 27339179 Get It

AbstractObjectivesTo investigate whether Gianotti–Crosti syndrome (GCS) in children is associated with atopy.MethodsThe setting was two outpatient clinic. Diagnoses of asthma and atopic dermatitis (AD) were made according to internationally accepted diagnostic criteria. Allergic rhinitis, atopic urticaria, and allergic conjunctivitis were diagnosed clinically. Participants were children with GCS diagnosed over the previous 5 years. For any child with GCS, we extracted the record of the subsequent age and sex pair‐matched child seen for problems unrelated to the skin as controls.ResultsWe retrieved the records of 37 pairs of study and control subjects; 28 (76%) children with GCS and 9 (24%) controls had AD (risk ratio [RR] = 3.11[95% confidence interval {CI} 1.73, 5.73]), 31 (84%) children with GCS and 19 (51%) controls had at least one atopic condition (RR = 1.63 [95% CI 1.13, 2.18]) and 11 (30%) children with GCS and 2 (5%) controls had at least three atopic conditions (RR = 5.50 [95% CI 1.29, 35.35]).ConclusionGCS is significantly associated with AD and the presence of atopic conditions.